New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease

Pharmacology and Therapeutics

Volumn 81, Issue 1, 1999, Pages 1-36

  Bonifati, Vincenzo ^a   Meco, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Catechol O methyltransferase; COMT inhibitors; Entacapone; Motor fluctuations; Parkinson's disease; Tolcapone

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA; N (6 OXO 1H PYRID 2 YL) N',N' DIPROPYLFORMAMIDINE; NITECAPONE; TOLCAPONE;

BIOAVAILABILITY; DRUG HALF LIFE; HUMAN; PARKINSON DISEASE; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; ENZYME INHIBITORS; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 0032949477     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00032-1     Document Type: Review

References (314)

1. Abrams W.B., Coutinho C.B., Leon A.S., Spiegel H.E. Absorption and metabolism of levodopa. JAMA. 218:1971;1912-1914.
2. Acquas E., Carboni E., de Ree R.H.A., Da Prada M., Di Chiara G. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J. Neurochem. 59:1992;326-330.
3. Agid Y., Destée A., Durif F., Montastruc J.-L., Pollak P., on behalf of the French Tolcapone Study Group Tolcapone, bromocriptine, and Parkinson's disease. Lancet. 350:1997;712-713.
4. Ahtila S., Kaakkola S., Gordin A., Korpela K., Heinävaara S., Karlsson M., Wikberg T., Tuomainen P., Männistö P.T. Effects of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin. Neuropharmacol. 18:1995;46-57.
5. Andersson I., Granerus A.K., Jagenburg R., Svanborg A. Intestinal decarboxylation of orally administered L-DOPA. Acta Med. Scand. 198:1975;415-420.
6. Armstrong M.D., McMillan A., Shaw K.N.F. 3-Methoxy-4-hydroxy-D-mandelic acid, a urinary metabolite of norepinephrine. Biochim. Biophys. Acta. 25:1957;422-423.
7. Assal F., Spahr L., Hadengue A., Rubbici-Brandt L., Burkhard P.R. Tolcapone and fulminant hepatitis. Lancet. 352:1998;958.
8. Assicot M., Bohuon C. Presence of two distinct catechol-O-methyltransferase activities in red blood cells. Biochimie. 53:1971;871-874.
9. Axelrod J., Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 233:1958;702-705.
10. Axelrod J., Senoh S., Witkop B. O-Methylation of catechol amines in vivo. J. Biol. Chem. 233:1958;697-701.
11. Baas H., Beiske A.G., Ghika J., Jackson M., Oertel W.H., Poewe W., Ransmayr G. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J. Neurol. Neurosurg. Psychiatry. 63:1997;421-428.
12. Bäckström R., Honkanen E., Pippuri A., Kairisalo P., Pystynen J., Heinola K., Nissinen E., Linden I.-B., Männistö P.T., Kaakkola S., Pohto P. Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J. Med. Chem. 32:1989;841-846.
13. Ball P., Knuppen R., Haupt M., Breuer H. Interactions between estrogens and catechol amines. III. Studies on the methylation of catechol estrogens, catechol amines and other catechols by the catechol-O-methyltransferase of human liver. J. Clin. Endocrinol. Metabol. 34:1972;736-746.
14. Baronti F., Mouradian M.M., Davis T.L., Giuffra M., Brughitta G., Conant K.E., Chase T.N. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann. Neurol. 32:1992;776-781.
15. Bartholini G., Pletscher A. Decarboxylase inhibitors. Pharmacol. Ther. 1:1975;407-421.
16. Bartholini G., Kuruma I., Pletscher A. 3-O-Methyldopa, a new precursor of dopamine. Nature. 230:1971;533-534.
17. Bartholini G., Kuruma I., Pletscher A. The metabolic pathways of L-3-O-methyldopa. J. Pharmacol. Exp. Ther. 183:1972;65-72.
18. Ben-Shlomo Y. How far are we in understanding the cause of Parkinson's disease? J. Neurol. Neurosurg. Psychiatry. 61:1996;4-16.
19. Bertocci B., Miggiano V., Da Prada M., Dembic Z., Lahm H.-W., Malherbe P. Human catechol-O-methyltransferase. cloning and expression of the membrane-associated form Proc. Natl. Acad. Sci. USA. 88:1991;1416-1420.
20. Bianchine J.R., Rivera-Calimlim L., Morgan J.P., Dujovne C.A., Lasagna L. Metabolism and absorption of L-3,4,dihydroxyphenylalanine inhibitor in patients with Parkinson's disease. Ann. NY Acad. Sci. 179:1971;126-140.
21. Bianchine J.R., Messiha F.S., Hsu T.H. Peripheral aromatic L-amino-acid decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2-14C-dopa. Clin. Pharmacol. Ther. 13:1972;584-594.
22. Bieck P.R., Nilsson E., Antonin K.H. Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects. J. Neural Transm. Suppl. 32:1990;387-391.
23. Bieck P.R., Antonin K.H., Farger G., Nilsson E.B., Schmidt E.K., Dostert P., Strolin Benedetti M., Waldmeier P.C. Clinical pharmacology of the new COMT inhibitor CGP 28,014. Neurochem. Res. 18:1993;1163-1167.
24. Borchardt R.T. Catechol-O-methyltransferase. 3. Mechanism of pyridoxal 5′-phosphate inhibition. J. Med. Chem. 16:1973;387-391.
25. Borchardt R.T., Cheng C.-F., Cooke P., Creveling C.R. The purification and kinetic properties of liver microsomal-catechol-O-methyltransferase. Life Sci. 14:1974;1089-1100.
26. Borges N., Vieira-Coelho M.A., Parada A., Soares-da-Silva P. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. J. Pharmacol. Exp. Ther. 282:1997;812-817.
27. Borgulya J., Bruderer H., Bernauer K., Zürcher G., Da Prada M. Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives. synthesis and structure-activity studies Helv. Chim. Acta. 72:1989;952-968.
28. Borgulya J., Da Prada M., Dingemanse J., Scherschlicht R., Schläppi B., Zürcher G. Ro 40-7592. Catechol-O-methyltransferase (COMT) inhibitor. Drugs Future. 16:1991;719-721.
29. Boudíková B., Szumlanski C., Maidak B., Weinshilboum R.M. Human liver catechol-O-methyltransferase pharmacogenetics. Clin. Pharmacol. Ther. 48:1990;381-389.
30. Brannan T., Martínez-Tica J., Yahr M.D. Effect of dietary protein on striatal dopamine formation following L-DOPA administration. an in vivo study Neuropharmacology. 30:1991;1125-1127.
31. Brannan T., Martínez-Tica J., Yahr M.D. Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine. an in vivo study in rats Neurology. 42:1992;683-685.
32. Brannan T., Prikhojan A., Yahr M.D. Peripheral and central inhibitors of catechol-O-methyltransferase. effects on liver and brain COMT activity and L-DOPA metabolism J. Neural Transm. 104:1997;77-87.
33. Bravi D., Mouradian M.M., Roberts J.W., Davis T.L., Sohn Y.H., Chase T.N. Wearing-off fluctuations in Parkinson's disease. contribution of postsynaptic mechanisms Ann. Neurol. 36:1994;27-31.
34. Briggs M.H., Briggs M. Hormonal influences on erythrocyte catechol-O-methyltransferase activity in humans. Experientia. 29:1973;278-280.
35. Buu N.T., Duhaime J., Kuchel O. Effects of L-dopa on concentrations of free and sulfoconjugated catecholamines in plasma, cerebrospinal fluid, urine and central and peripheral nervous system tissues of the rat. J. Neurochem. 44:1985;787-792.
36. Byrne J.M., Tipton K.F. Nitrocatechol derivatives as inhibitors of catechol-O-methyltransferase. Biochem. Soc. Trans. 24:1996;64S.
37. Calne D.B. Treatment of Parkinson's disease. N. Engl. J. Med. 329:1993;1021-1027.
38. Calne D.B., Karoum F., Ruthven C., Sandler M. The metabolism of orally administered L-dopa in parkinsonism. Br. J. Pharmacol. 37:1969;57-68.
39. Calne D.B., Reid J.L., Vakil S.D., Rao S., Petrie A., Pallis C.A., Gawler J., Thomas P.K., Hilson A. Idiopathic parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br. Med. J. 3:1971;729-732.
40. Calne D.B., Reid J.L., Vakil S.D. Parkinsonism treated with 3-O-methyldopa. Clin. Pharmacol. Ther. 14:1973;386-389.
41. Cedarbaum J.M. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin. Pharmacokinet. 13:1987;141-178.
42. Cedarbaum J.M., Kutt H., Dhar A.K., Watkins S., McDowell F.H. Effect of supplemental carbidopa on the bioavailability of L-dopa. Clin. Neuropharmacol. 9:1986;153-159.
43. Cedarbaum J.M., Kutt H., McDowell F.H. Clinical significance of the relationship between O-methyldopa levels and levodopa intake. Neurology. 38:1988;533-536.
44. Cedarbaum J.M., Leger G., Guttman M. Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys. implications for the treatment of Parkinson's disease Clin. Neuropharmacol. 14:1991;330-342.
45. Chase T.N., Engber T.M., Mouradian M.M. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinsons' disease. Neurology. 44(Suppl. 6):1994;S15-S18.
46. Colosimo C., Merello M., Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin. Neuropharmacol. 17:1994;243-259.
47. Colosimo C., Merello M., Hughes A.J., Sieradzan K., Lees A.J. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease. implications for the pathogenesis of the on-off phenomenon J. Neurol. Neurosurg. Psychiatry. 61:1996;634-637.
48. Cotzias G.C., Van Woert M.H., Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276:1967;374-379.
49. Cotzias G.C., Papavasiliou P.S., Ginos J., Steck A., Duby S. Metabolic modification of Parkinson's disease and of chronic manganese poisoning. Annu. Rev. Med. 22:1971;305-326.
50. Coudoré F., Durif F., Duroux E., Eschalier A., Fialip J. Effect of tolcapone on plasma and striatal apomorphine disposition in rats. Neuroreport. 8:1997;877-880.
51. Coward J.K., Slixz E.P., Wu F.Y. Kinetic studies on catechol O-methyltransferase. Product inhibition and the nature of the catechol binding site. Biochemistry. 12:1973;2291-2297.
52. Crossman A.R. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease. implications for future strategies in treatment Mov. Disord. 5:1990;100-108.
53. Cumming P., Boyes B.E., Martin W.R.W., Adam M., Ruth T.J., McGeer E.G. Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521. Biochem. Pharmacol. 36:1987;2527-2531.
54. Cummings J.L. Depression and Parkinson's disease. a review Am. J. Psychiatry. 149:1992;443-454.
55. Da Prada M., Jorga K.M. Response to Garrido et al. "Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits." Clin. Neuropharmacol. 19:1996;98-99.
56. Da Prada M., Borgulya J., Napolitano A., Zürcher G. Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine-sparing effect. Clin. Neuropharmacol. 17(Suppl. 3):1994;S26-S37.
57. Davis T.L., Roznoski M., Burns R.S. Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Clin. Neuropharmacol. 18:1995;333-337. a.
58. Davis T.L., Roznoski M., Burns R.S. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov. Disord. 10:1995;349-351. b.
59. Deleu D., Sarre S., Ebinger G., Michotte Y. The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog. an in vivo microdialysis study J. Pharmacol. Exp. Ther. 273:1995;1323-1331.
60. de Rijk M.C., Tzourio C., Breteler M.M.B., Dartigues J.F., Amaducci L., Lopez-Pousa S., Manubens-Bertran J.M., Alpérovitch A., Rocca W.A. Prevalence of parkinsonism and Parkinson's disease in Europe. the EUROPARKINSON collaborative study J. Neurol. Neurosurg. Psychiatry. 62:1997;10-15.
61. Diamond S.G., Markham C.H., Treciokas L.J. A double-blind comparison of levodopa, Madopar and Sinemet in Parkinson disease. Ann. Neurol. 3:1978;267-272.
62. Dingemanse J., Jorga K., Schmitt M., Gieschke R., Fotteler B., Zürcher G., Da Prada M., van Brummelen P. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin. Pharmacol. Ther. 57:1995;508-517. a.
63. Dingemanse J., Jorga K., Zürcher G., Schmitt M., Sedek G., Da Prada M., van Brummelen P. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br. J. Clin. Pharmacol. 40:1995;253-262. b.
64. Dingemanse J., Jorga K., Zürcher G., Fotteler B., Sedek G., Nielsen T., van Brummelen P. Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur. J. Clin. Pharmacol. 50:1996;47-55.
65. Doudet D.J., Chan G.L.Y., Holden J.E., Morrison K.S., Wyatt R.J., Ruth T.J. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology. 36:1997;363-371. a.
66. 18F]L-DOPA Eur. J. Pharmacol. 334:1997;31-38. b.
67. Dunner D.L., Brodie H.K.H., Goodwin F.K. Plasma DOPA response to levodopa administration in man. effects of a peripheral decarboxylase inhibitor Clin. Pharmacol. Ther. 12:1971;212-217.
68. Dupont, E., Burgunder, J.-M., Findley, L. J., Olsson, J.-E., Dorflinger, E. and the Tolcapone in Parkinson's Disease Study Group II (TIPS II) (1997) Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Mov. Disord. 12: 928-934.
69. Eisenhofer G. Plasma normetanephrine for examination of extraneuronal uptake and metabolism of noradrenaline in rats. Naunyn Schmiedebergs Arch. Pharmacol. 349:1994;259-269.
70. Ericsson A.D. Potentiation of the L-dopa effect in man by the use of catechol-O-methyltransferase inhibitors. J. Neurol. Sci. 14:1971;193-197.
71. Etemadzadeh E., Koskinen L., Kaakkola S. Computerized rotometer apparatus for recording circling behavior. Methods Find. Exp. Clin. Pharmacol. 11:1989;399-407.
72. Evans M.A., Triggs E.J., Broe G.A., Saines N. Systemic activity of orally administered L-DOPA in the elderly parkinsonian patient. Eur. J. Clin. Pharmacol. 17:1980;215-221.
73. Evans M.A., Broe G.A., Triggs E.J., Cheung M., Creasey H., Paull P.D. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient. Neurology. 31:1981;1288-1294.
74. Fabbrini G., Juncos J.L., Mouradian M.M., Serrati C., Chase T.N. 3-O-Methyldopa and motor fluctuations in Parkinson's disease. Neurology. 37:1987;856-859.
75. Fabbrini G., Mouradian M.M., Juncos J.L., Schlegel J., Mohr E., Chase T.N. Motor fluctuations in Parkinson's disease. central pathophysiological mechanisms, part I Ann. Neurol. 24:1988;366-371.
76. Fahn S. "On-off" phenomenon with levodopa therapy in parkinsonism. Neurology. 24:1974;431-441.
77. Ferrini R., Glässer A. In vitro decarboxylation of new phenylalanine derivatives. Biochem. Pharmacol. 13:1964;798-801.
78. Feuerstein C., Tanche M., Serre F., Gavend M., Pellat J., Perret J. Does O-methyldopa play a role in levodopa-induced dyskinesia? Acta Neurol. Scand. 56:1977;79-82.
79. Firnau G., Sood S., Chirakal R., Nahmias C., Garnett E.S. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J. Neurochem. 48:1987;1077-1082.
80. Floderus Y., Wetterberg L. The inheritance of human erythrocyte catechol-O-methyltransferase activity. Clin. Genet. 19:1981;392-395.
81. Floderus Y., Ross S.B., Wetterberg L. Erythrocyte catechol-O-methyltransferase activity in a Swedish population. Clin. Genet. 19:1981;389-392.
82. Flohe L., Schwabe K.P. Kinetics of purified catechol O-methyltransferase. Biochim. Biophys. Acta. 220:1970;469-476.
83. Fredriksson A., Archer T. Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice. J. Neural Transm. (Gen. Sect.). 102:1995;19-34.
84. 1 and catechol-O-methyltransferase in removal of circulating catecholamines in the rabbit. Am. J. Physiol. 267 (Endocrinol. Metab. 30): E814-E821.
85. ® on the disposition of tolcapone and its 3-O-methylated metabolite in rats. J. Pharm. Pharmacol. 47:1995;539-542.
86. Gancher S.T., Nutt J.G., Woodward W.R. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology. 37:1987;940-944.
87. Garnett E.S., Firnau G., Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature. 305:1983;137-138.
88. Garrido J.M., Mena M.A., Correa C., Herreras O., Jorge P., Leenders K., Antonini A., Günther I., Psylla M., de Yébenes J.G. Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits. Clin. Neuropharmacol. 17:1994;270-276.
89. Gasparini M., Fabrizio E., Bonifati V., Meco G. Cognitive improvement during tolcapone treatment in Parkinson's disease. J. Neural Transm. 104:1997;887-894.
90. Gasser T., Müller-Myhsok B., Wszolek Z.K., Oehlmann R., Calne D.B., Bonifati V., Bereznai B., Fabrizio E., Vieregge P., Horstmann R.D. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nature Genet. 18:1998;262-265.
91. Gervas J.J., Muradás V., Bazán E., Aguado E.G., de Yébenes J.G. Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology. 33:1983;278-282.
92. Goodall M.C., Alton H. Metabolism of 3,4-dihydroxyphenylalanine (L-DOPA) in human subjects. Biochem. Pharmacol. 21:1972;2401-2408.
93. Granerus A.K., Jagenburg R., Svanborg A. Intestinal decarboxylation of L-DOPA in relation to dose requirement in Parkinson's disease. Naunyn Schmiedebergs Arch. Pharmacol. 280:1973;429-439.
94. Grossman M.H., Emanuel B.S., Budarf M.L. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2. Genomics. 12:1992;822-825. a.
95. Grossman M.H., Szumlanski C., Littrell J.B., Weinstein R., Weinshilboum R.M. Electrophoretic analysis of low and high activity forms of catechol-O-methyltransferase in human erythrocytes. Life Sci. 50:1992;473-480. b.
96. Guldberg H.C., Marsden C.A. Catechol-O-methyl transferase. pharmacological aspects and physiological role Pharmacol. Rev. 27:1975;135-206.
97. 18F]fluoro-L-dopa in rhesus monkey Nucl. Med. Biol. 22:1995;921-927.
98. Guttman M., Léger G., Cedarbaum J.M., Reches A., Woodward W., Evans A., Diksic M., Gjedde A. 3-O-Methyldopa administration does not alter fluorodopa transport into the brain. Ann. Neurol. 31:1992;638-643.
99. Guttman M., Léger G., Reches A., Evans A., Kuwabara H., Cedarbaum J.M., Gjedde A. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov. Disord. 8:1993;298-304.
100. Halbrügge T., Friedgen B., Ludwig J., Graefe K.-H. Effects of catechol-O-methyltransferase inhibition on the plasma clearance of noradrenaline and the formation of 3,4-dihydroxyphenylglycol in the rabbit. Naunyn Schmiedebergs Arch. Pharmacol. 347:1993;162-170.
101. Hardebo J.E., Emson P.C., Falck B., Owman C., Rosengren E. Enzymes related to monoamine transmitter metabolism in brain microvessels. J. Neurochem. 35:1980;1388-1393.
102. ångström B. Regional brain kinetics of 6-fluoro-(β-11C)-L-dopa and (β-11C)L-dopa following COMT inhibition. A study in vivo using positron emission tomography. J. Neural Transm. (Gen. Sect.). 87:1992;15-22.
103. Himori N., Mishima K. The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP+-lesioned mice. Experientia. 50:1994;939-942.
104. Hoda F., Nicholl D.J., Bennett P., Arranz M., Aitchison K.J., Al-Chalabi A., Kunugi H., Vallada H., Leigh P.N., Ray Chaudhuri K., Collier D.A. No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase. Biochem. Biophys. Res. Commun. 228:1996;780-784.
105. 18F]fluoro-L-DOPA kinetics in positron emission tomography. J. Nucl. Med. 33:1992;1472-1477.
106. Holden J.E., Doudet D., Endres C.J., Chan G.L., Morrison K.S., Vingerhoets F.J., Snow B.J., Pate B.D., Sossi V., Buckley K.R., Ruth T.J. Graphical analysis of 6-fluoro-L-dopa trapping. effect of inhibition of catechol-O-methyltransferase J. Nucl. Med. 38:1997;1568-1574.
107. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45:1986;19-34.
108. Hughes A.J., Daniel S.E., Kilford L., Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease. a clinico-pathological study of 100 cases J. Neurol. Neurosurg. Psychiatry. 55:1992;181-184.
109. Illi A., Sundberg S., Koulu M., Scheinin M., Heinavaara S., Gordin A. COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int. J. Clin. Pharmacol. Ther. 32:1994;582-588.
110. Illi A., Sundberg S., Ojala-Karlsson P., Korhonen P., Scheinin M., Gordin A. The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. Clin. Pharmacol. Ther. 58:1995;221-227.
111. Illi A., Sundberg S., Ojala-Karlsson P., Scheinin M., Gordin A. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A. effects on hemodynamics and catecholamine metabolism in healthy volunteers Clin. Pharmacol. Ther. 59:1996;450-457. a.
112. Illi A., Sundberg S., Ojala-Karlsson P., Scheinin M., Gordin A. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine. lack of interactions Eur. J. Clin. Pharmacol. 51:1996;273-276. b.
113. Ishikawa T., Dhawan V., Chaly T., Robeson W., Belakhlef A., Mandel F., Dahl R., Margouleff C., Eidelberg D. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase. effect of the plasma 3-O-methyldopa fraction on data analysis J. Cereb. Blood Flow Metab. 16:1996;854-863.
114. Jeffery D.R., Roth J.A. Purification and kinetic mechanism of human brain soluble catechol-O-methyltransferase. J. Neurochem. 44:1985;881-885.
115. Jorga K., Fotteler B., Schmitt M., Nielsen T., Zürcher G., Aitken J. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur. Neurol. 38:1997;59-67. a.
116. Jorga K.M., Larsen J.P., Beiske A., Fotteler B., Moe B. Effect of tolcapone on benserazide pharmacokinetics. J. Neurol. 244(Suppl. 3):1997;S26. b.
117. Jorga K.M., Sedek G., Fotteler B., Zürcher G., Nielsen T., Aitken J.W. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin. Pharmacol. Ther. 62:1997;300-310. c.
118. Kaakkola S., Wurtman R.J. Effects of COMT inhibitors on striatal dopamine metabolism. a microdialysis study Brain Res. 587:1992;241-249.
119. Kaakkola S., Wurtman R.J. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J. Neurochem. 60:1993;137-144.
120. Kaakkola S., Männistö P.T., Nissinen E. Striatal membrane-bound and soluble catechol-O-methyltransferase after selective neuronal lesions in the rat. J. Neural Transm. 69:1987;221-228.
121. Kaakkola S., Gordin A., Jarvinen M., Wikberg T., Schultz E., Nissinen E., Pentikäinen P.J., Rita H. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin. Neuropharmacol. 13:1990;436-447.
122. Kaakkola S., Gordin A., Männistö P.T. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen. Pharmacol. 25:1994;813-824. a.
123. Kaakkola S., Teräväinen H., Ahtila S., Rita H., Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology. 44:1994;77-80. b.
124. Kaplan G.P., Hartman B.K., Creveling C.R. Immunohistochemical demonstration of catechol-O-methyltransferase in mammalian brain. Brain Res. 167:1979;241-250.
125. Karhunen T., Tilgmann C., Ulmanen I., Julkunen I., Panula P. Distribution of cathechol-O-methyltransferase enzyme in rat tissues. J. Histochem. Cytochem. 42:1994;1079-1090.
126. Karhunen T., Tilgmann C., Ulmanen I., Panula P. Catechol-O-methyltransferase (COMT) in rat brain. immunoelectron microscopic study with an antiserum against rat recombinant COMT protein Neurosci. Lett. 187:1995;57-60.
127. Karlsson M., Wikberg T. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J. Pharm. Biomed. Anal. 10:1992;593-600.
128. Kastner A., Anglade P., Bounaix C., Damier P., Javoy-Agid F., Bromet N., Agid Y., Hirsch E.C. Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system. Neuroscience. 62:1994;449-457.
129. Kaufmann H. Could treatment with DOPS do for autonomic failure what DOPA did for Parkinson's disease? Neurology. 47:1996;1370-1371.
130. Keränen T., Gordin A., Harjola V.-P., Karlsson M., Korpela K., Pentikäinen P.J., Rita H., Seppälä L., Wikberg T. The effects of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin. Neuropharmacol. 16:1993;145-156.
131. Keränen T., Gordin A., Karlsson M., Korpela K., Pentikäinen P.J., Rita H., Schultz E., Seppälä L., Wikberg T. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur. J. Clin. Pharmacol. 46:1994;151-157.
132. Keränen T., Gordin A., Koulu M., Scheinin M., Antila S., Sundberg S., Wikberg T. COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers. J. Neural Transm. 103:1996;729-736.
133. Khromova I., Rauhala P., Zolotov N., Männistö P.T. Tolcapone, an inhibitor of catechol O-methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the basal nuclei of Meynert. Neuroreport. 6:1995;1219-1222.
134. Khromova I., Voronina T., Kraineva V.A., Zolotov N., Männistö P.T. Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats. Behav. Brain Res. 86:1997;49-57.
135. Klemetsdal B., Straume B., Giverhaug T., Aarbakke J. Low catechol-O-methyltransferase activity in a Saami population. Eur. J. Clin. Pharmacol. 46:1994;231-235.
136. Kopin I.J. Catecholamine metabolism. basic aspects and clinical significance Pharmacol. Rev. 37:1985;333-364.
137. Kopin I.J. Monoamine oxidase and catecholamine metabolism. J. Neural Transm. Suppl. 41:1994;57-67.
138. Kunugi H., Nanko S., Ueki A., Otsuka E., Hattori M., Hoda F., Vallada H.P., Arranz M.J., Collier D.A. High and low activity alleles of catechol-O-methyltransferase gene. ethnic difference and possible association with Parkinson's disease Neurosci. Lett. 221:1997;202-204.
139. Kurth, M. C., Adler, C. H., St. Hilaire, M., Singer, C., Waters, C., LeWitt, P., Chernik, D. A., Dorflinger, E. E., Yoo, K. and the Tolcapone Fluctuator Study Group I (1997) Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 48: 81-87.
140. Kuruma I.L., Bartholini G., Tissot R., Pletscher A. The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin. Pharmacol. Ther. 12:1971;678-682.
141. 18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462). Neurology. 42:1992;199-203.
142. Lautala P., Kivimaa M., Salomies H., Elovaara E., Taskinen J. Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocathecols by rat liver microsomes. Pharm. Res. 14:1997;1444-1448.
143. Lave Th., Dupin S., Schmitt M., Kapps M., Meyer J., Morgenroth B., Chou R.C., Jaeck D., Coassolo Ph. Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica. 26:1996;839-851.
144. Lhermitte F., Agid Y., Feuerstein C., Serre F., Signoret J.-L., Studler J.M., Bonnet A.M. Mouvements anormaux provoqués par la L-dopa dans la maladie de Parkinson. corrélation avec les concentrations plasmatiques de dopa et de O-méthyldopa Rev. Neurol. 133:1977;445-454.
145. Liljequist R., Haapalinna A., Ahlander M., Li Y.H., Männistö P.T. Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav. Brain Res. 82:1997;195-202.
146. Limousin P., Pollak P., Gervason-Tournier C.-L., Hommel M., Perret J.E. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease. Lancet. 341:1993;1605.
147. Limousin P., Pollak P., Pfefen J.P., Tournier-Gervason C.L., Dubuis R., Perret J.E. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin. Neuropharmacol. 18:1995;258-265.
148. Linden I.B. Effects of 3,4-dihydroxyphenylpyruvic acid and L-glutamic acid on some pharmacokinetic parameters of L-DOPA in the rat. J. Pharm. Pharmacol. 32:1980;344-348.
149. Lindén I.-B., Nissinen E., Etemadzadeh E., Kaakkola S., Männistö P., Pohto P. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. J. Pharmacol. Exp. Ther. 247:1988;289-293.
150. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melén K., Julkunen I., Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyl-transferase. a revised mechanism and description of the thermolabile variant of the enzyme Biochemistry. 34:1995;4202-4210.
151. Lundström K., Salminen M., Jalanko A., Savolainen R., Ulmanen I. Cloning and characterisation of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol. 10:1991;181-189.
152. Lundström K., Tilgmann C., Peränen J., Kalkkinen N., Ulmanen I. Expression of enzymatically active rat liver and human placental catechol-O-methyltransferase in Escherichia coli; purification and partial characterization of the enzyme. Biochim. Biophys. Acta. 1129:1992;149-154.
153. Lyytinen J., Kaakkola S., Ahtila S., Tuomainen P., Teräväinen H. Simultaneous MAO-B and COMT inhibition in L-DOPA-treated patients with Parkinson's disease. Mov. Disord. 12:1997;497-505.
154. Maj J., Rogóz Z., Skuza G., Sowinska H., Superata J. Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J. Neural Transm. (P-D Sect.). 2:1990;101-112.
155. Malherbe P., Bertocci B., Caspers P., Zürcher G., Da Prada M. Expression of functional membrane-bound and soluble catechol-O-methyltransferase in Escherichia coli and a mammalian cell line. J. Neurochem. 58:1992;1782-1789.
156. Männistö P.T., Kaakkola S. New selective COMT inhibitors. useful adjuncts for Parkinson's disease? Trends Pharmacol. Sci. 10:1989;54-56.
157. Männistö P.T., Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol. Toxicol. 66:1990;317-323.
158. Männistö P.T., Kaakkola S., Nissinen E., Linden I.-B., Pohto P. Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci. 43:1988;1465-1471.
159. Männistö P.T., Tuomainen P., Tuominen R.K. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br. J. Pharmacol. 105:1992;569-574. a.
160. Männistö P.T., Ulmanen I., Lundström K., Taskinen J., Tenhunen J., Tilgmann C., Kaakkola S. Characteristics of catechol O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog. Drug Res. 39:1992;291-350. b.
161. Männistö P.T., Lang A., Rauhala P., Vasar E. Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression. Eur. J. Pharmacol. 274:1995;229-233.
162. Marcocci L., Maguire J.J., Packer L. Nitecapone. a nitric oxide radical scavenger Biochem. Mol. Biol. Int. 34:1994;531-541.
163. Marconi R., Lefebvre-Caparros D., Bonnet A.-M., Vidailhet M., Dubois B., Agid Y. Levodopa-induced dyskinesias in Parkinson's disease. phenomenology and pathophysiology Mov. Disord. 9:1994;2-12.
164. Mars H. Modification of levodopa effect by systemic decarboxylase inhibition. Arch. Neurol. 28:1973;91-95.
165. Marsden C.D. Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 57:1994;672-681.
166. Martin W.R.W., Palmer M.R., Patlak C.S., Calne D.B. Nigrostriatal function in humans studied with positron emission tomography. Ann. Neurol. 26:1989;535-542.
167. Mcleod H.L., Fang L., Luo X., Scott E.P., Evans W. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J. Pharmacol. Exp. Ther. 270:1994;26-29.
168. 18F]fluoro-DOPA metabolism in monkeys and humans. biochemical parameters for the formulation of tracer kinetic models with positron emission tomography J. Cereb. Blood Flow Metab. 11:1991;890-897.
169. Mena I., Cotzias G.C. Protein intake and treatment of Parkinson's disease with levodopa. N. Engl. J. Med. 292:1975;181-184.
170. Merello M., Lees A.J., Webster R., Bovingdon M., Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 57:1994;186-189.
171. Messiha F., Hsu T., Bianchine J. Peripheral aromatic L-amino acid decarboxylase inhibitor in parkinsonism. I. Effect on O-methylated metabolites of L-. DOPA. -2-14C:1972;. Clin. Invest. 51: 452-455.J.
172. 18F]Fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys. Brain Res. 626:1993;1-13.
173. Moreau J.L., Borgulya J., Jenck F., Martin J.R. Tolcapone. a potential new antidepressant detected in a novel animal model of depression Behav. Pharmacol. 5:1994;344-350.
174. Morgan J.P., Bianchine J.R., Spiegel H.E., Rivera-Calimlin L., Hersey R.M. Metabolism of levodopa in patients with Parkinson's disease. Arch. Neurol. 25:1971;39-44.
175. Morris J.G.L., Parsons R.L., Trounce J.R., Groves M.J. Plasma DOPA concentrations after different preparations of levodopa in normal subjects. Br. J. Clin. Pharmacol. 3:1976;983-990.
176. Mouradian M.M., Juncos J.L., Fabbrini G., Schlegel J., Bartko J.J., Chase T.N. Motor fluctuations in Parkinson's disease. central pathophysiological mechanisms, part II Ann. Neurol. 24:1988;372-378.
177. Mouradian M.M., Heuser I.J.E., Baronti F., Chase T.N. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann. Neurol. 27:1990;18-23.
178. Muenter M.D., Tyce G.M. L-DOPA therapy of Parkinson's disease. plasma L-DOPA concentration, therapeutic response, and side effects Mayo Clin. Proc. 46:1971;231-239.
179. Muenter M.D., Sharpless N.S., Tyce G.M. Plasma 3-O-methyldopa in L-dopa therapy of Parkinson's disease. Mayo Clin. Proc. 47:1972;389-395.
180. Muenter M.D., Dinapoli R.P., Sharpless N.S., Tyce G.M. 3-O-Methyldopa, L-dopa and trihexyphenidyl in the treatment of Parkinson's disease. Mayo Clin. Proc. 48:1973;173-183.
181. Muenter M.D., Sharpless N.S., Tyce G.M., Darley F.L. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-DOPA therapy for Parkinson's disease. Mayo Clin. Proc. 52:1977;163-174.
182. Müller Th., Kuhn W., Przuntek H. Therapy with central active cetachol-O-methyltransferase (COMT)-inhibitors. is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? J. Neural Transm. (Gen. Sect.). 92:1993;187-195.
183. Myllylä V.V., Sotaniemi K.A., Illi A., Suominen K., Keränen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur. J. Clin. Pharmacol. 45:1993;419-423.
184. Napolitano A., Cesura A.M., Da Prada M. The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. J. Neural Transm. Suppl. 45:1995;35-45. a.
185. Napolitano A., Zürcher G., Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in rats. Eur. J. Pharmacol. 273:1995;215-221. b.
186. Naudon L., Dourmap N., Leroux-Nicollett I., Costentin J. Kainic acid lesion of the striatum increases dopamine release but reduces 3-methoxytyramine level. Brain Res. 572:1992;247-249.
187. Nic a'Bháird N., Goldberg R., Tipton K.F. Catechol-O-methyltransferase and its role in catecholamine metabolism. Adv. Neurol. 53:1990;489-495.
188. Nissinen E., Lindén I.-B., Schultz E., Kaakkola S., Männistö P.T., Pohto P. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur. J. Pharmacol. 153:1988;263-269. a.
189. Nissinen E., Tuominen R., Perhoniemi V., Kaakkola S. Catechol-O-methyltransferase activity in human and rat small intestine. Life Sci. 42:1988;2609-2614. b.
190. Nissinen E., Lindén I.-B., Schultz E., Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor Entacapone. Naunyn Schmiedebergs Arch. Pharmacol. 346:1992;262-266.
191. Nutt J.G. Levodopa-induced dyskinesia. review, observations, and speculations Neurology. 40:1990;340-345.
192. Nutt J.G. Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA. Adv. Neurol. 69:1996;493-496.
193. Nutt J.G., Fellman J.H. Pharmacokinetics of levodopa. Clin. Neuropharmacol. 7:1984;35-49.
194. Nutt J.G., Holford N.H.G. The response to levodopa in Parkinson's disease. imposing pharmacological law and order Ann. Neurol. 39:1996;561-573.
195. Nutt J.G., Woodward W.R., Anderson J.L., Hammerstad J.P. What is the function of carbidopa in the treatment of parkinsonism? Ann. Neurol. 14:1983;133-134.
196. Nutt J.G., Woodward W.R., Hammerstad J.P., Carter J.H., Anderson J.L. The "on-off" phenomenon in Parkinson's disease. relation to L-DOPA absorption and transport N. Engl. J. Med. 310:1984;483-488.
197. Nutt J.G., Woodward W.R., Anderson J.L. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa. the mechanism of action in the treatment of parkinsonism Ann. Neurol. 18:1985;537-543.
198. Nutt J.G., Woodward W.R., Gancher S.T., Merrick D. 3-O-Methyldopa and the response to levodopa in Parkinson's disease. Ann. Neurol. 21:1987;584-588.
199. Nutt J.G., Woodward W.R., Beckner R.M., Stone C.K., Berggren K., Carter J.H., Gancher S.T., Hammerstad J.P., Gordin A. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 44:1994;913-919.
200. Nutt J.G., Carter J.H., Van Houten L., Woodward W.R. Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann. Neurol. 42:1997;349-355.
201. Nuutila J., Kaakkola S., Männistö P.T. Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase. J. Neural Transm. 70:1987;233-240.
202. Orama M., Tilus P., Taskinen J., Lotta T. Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution. J. Pharm. Sci. 86:1997;827-831.
203. Ordonez L.A., Arbrus M., Boyson S., Goodman M.N., Ruderman N.B., Wurtman R.J. Skeletal muscle. reservoir for exogenous L-dopa J. Pharmacol. Exp. Ther. 190:1974;187-191.
204. Pardridge W.M. Kinetics of competitive inhibition of neutral amino acid transport across the blood-brain barrier. J. Neurochem. 28:1977;103-108.
205. Parkinson Study Group Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann. Neurol. 42:1997;747-755.
206. 18F]fluoro-L-dopa. Eur. J. Pharmacol. 257:1994;53-58.
207. Pentikäinen P.J., Vuorela A., Järvinen M., Wikberg T., Gordin A. Human pharmacokinetics of OR-462, a new catechol-O-methyltransferase inhibitor. Eur. J. Clin. Pharmacol. 36(Suppl.):1989;A110.
208. Polymeropoulos M.H., Higgins J.J., Golbe L.I., Johnson W.G., Ide S.E., Di Iorio G., Sanges G., Stenroos E.S., Pho L.T., Schaffer A.A., Lazzarini A.M., Nussbaum R.L., Duvoisin R.C. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science. 274:1996;1197-1199.
209. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
210. 18F]fluoro-L-DOPA uptake in rhesus monkey. pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition Brain Res. 767:1997;45-54.
211. Quattrone A., Zappia M., Aguglia U., Branca D., Colao R., Montesanti R., Nicoletti G., Palmieri A., Parlato G., Rizzo M. The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann. Neurol. 38:1995;389-395.
212. Rajput A.H., Rozdilsky B., Rajput A. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can. J. Neurol. Sci. 18:1991;275-278.
213. Rajput A.H., Martin W., Saint-Hilaire M.-H., Dorflinger E., Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon. a double-blind, placebo-controlled, multicenter trial Neurology. 49:1997;1066-1071.
214. Reches A., Fahn S. 3-O-Methyldopa blocks dopa metabolism in rat corpus striatum. Ann. Neurol. 12:1982;267-271.
215. Reches A., Fahn S. Catechol-O-methyltransferase and Parkinson's disease. Adv. Neurol. 40:1984;171-179.
216. Reches A., Mielke L.R., Fahn S. 3-O-Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology. 32:1982;887-888.
217. Reilly D.K., Rivera-Calimlim L., Van Dyke D. Catechol-O-methyltransferase activity. a determinant of levodopa response Clin. Pharmacol. Ther. 28:1980;278-286.
218. Rinne U.K., Sonninen V., Siirtola T. Plasma concentration of levodopa in patients with Parkinson's disease. Eur. Neurol. 10:1973;301-310.
219. Rivera-Calimlim L., Reilly D.K. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians. difference in levodopa tolerance Clin. Pharmacol. Ther. 35:1984;804-809.
220. Rivera-Calimlim L., Dujovne C.A., Morgan J.P., Lasagna L., Bianchine J.R. L-DOPA treatment failure. explanation and correction Br. Med. J. 4:1970;93-94.
221. Rivera-Calimlim L., Tandon D., Anderson F., Joynt R. The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor. Arch. Neurol. 34:1977;228-232.
222. Rivett A.J., Roth J.A. Kinetic studies on the O-methylation of dopamine by human brain membrane-bound catechol O-methyltransferase. Biochemistry. 21:1982;1740-1742.
223. Rivett A.J., Francis A., Roth J.A. Distinct cellular localization of membrane bound and soluble forms of catechol-O-methyltransferase in brain. J. Neurochem. 40:1983;215-219. a.
224. Rivett A.J., Francis A., Roth J.A. Localization of membrane-bound catechol-O-methyltransferase. J. Neurochem. 40:1983;1494-1496. b.
225. Roberts J.W., Cora-Locatelli G., Bravi D., Amantea M.A., Mouradian M.M., Chase T. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology. 43:1993;2685-2688.
226. Rodriguez M., Lera G., Vaamonde J., Luquin M.R., Obeso J.A. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 57:1994;562-566.
227. Rose S., Jenner P., Marsden C.D. The effect of carbidopa on plasma and muscle levels of l-dopa, dopamine and their metabolites following L-dopa administration to rats. Mov. Disord. 3:1988;117-125.
228. Rossor M.N., Watkins J., Brown M.J., Reid J.L., Dollery C.T. Plasma levodopa, dopamine and therapeutic response following levodopa therapy of parkinsonian patients. J. Neurol. Sci. 46:1980;385-392.
229. Roth J.A. Membrane-bound catechol-O-methyltransferase. a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters Rev. Physiol. Biochem. Pharmacol. 120:1992;1-29.
230. Ruottinen H.M., Rinne U.K. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced Parkinsonian patients. Clin. Neuropharmacol. 19:1996;222-233. a.
231. Ruottinen H.M., Rinne U.K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin. Neuropharmacol. 19:1996;283-296. b.
232. Ruottinen H.M., Rinne U.K. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J. Neurol. Neurosurg. Psychiatry. 60:1996;36-40. c.
233. 18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J. Neural Transm. (P.-D. Sect.). 10:1995;91-106.
234. 18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B. differing response in relation to presynaptic dopaminergic dysfunction Synapse. 27:1997;336-346.
235. Russ H., Gerlach M., Dettner O., Kuhn W., Przuntek H. -)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyltransferase activity. J. Neural Transm. (P-D Sect.). 3:1991;215-223.
236. Salminen M., Lundström K., Tilgmann C., Savolainen R., Kalkkinen N., Ulmanen I. Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene. 93:1990;241-247.
237. Sandler M., Johnson R.D., Ruthven C.R.J., Reid J.L., Calne D.B. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition. Nature. 247:1974;364-366.
238. Sasahara K., Nitanai T., Habara T., Morioka T., Nakajima E. Dosage form design for improvement of bioavailability of levodopa. II. Bioavailability of marketed levodopa preparations in dogs and parkinsonian patients. J. Pharm. Sci. 69:1980;261-265. a.
239. Sasahara K., Nitanai T., Habara T., Morioka T., Nakajima E. Dosage form design for improvement of bioavailability of levodopa. III. Influence of dose on pharmacokinetic behavior of levodopa in dogs and parkinsonian patients. J. Pharm. Sci. 69:1980;1374-1378. b.
240. Sasahara K., Nitanai T., Habara T., Kojima T., Kawahara Y., Morioka T., Nakajima E. Dosage form design for improvement of bioavailability of levodopa. IV. Possible causes of low bioavailability of oral levodopa in dogs. J. Pharm. Sci. 70:1981;730-733.
241. 18F]-6-L-fluorodopa metabolism. implications for levodopa therapy of Parkinson's disease Neurology. 44:1994;1292-1297.
242. Scanlon P.D., Raymond F.A., Weinshilboum R.M. Catechol-O-methyltransferase. thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity Science. 203:1979;63-65.
243. Schultz E., Nissinen E. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochem. Pharmacol. 38:1989;3953-3956.
244. Schultz E., Nissinen E., Kaakkola S. Determination of catechol-O-methyltransferase activity in erythrocytes by high performance liquid chromatography with electrochemical detection. Biomed. Chromatogr. 3:1989;64-67.
245. Schultz E., Tarpila S., Bäckström A.-C., Gordin A., Nissinen E., Pohto P. Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone. Eur. J. Clin. Pharmacol. 40:1991;577-580.
246. Sêdek G., Jorga K., Schmitt M., Burns R.S., Leese P. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin. Neuropharmacol. 20:1997;531-541.
247. Sharpless N.S., Muenter M.D., Tyce G.M., Owen C.A. 3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease. Clin. Chim. Acta. 37:1972;359-369.
248. Sharpless N.S., Tyce G.M., Owen C.A. Effect of chronic administration of L-dopa on catechol-O-methyltransferase in rat tissues. Life Sci. 12:1973;97-106.
249. Smith L.A., Gordin A., Jenner P., Marsden C.D. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov. Disord. 12:1997;935-945.
250. Spatz M., Kaneda N., Sumi C., Nagatsu I., Creveling C.R., Nagatsu T. The presence of catechol-O-methyltransferase activity in separately cultured cerebromicrovascular endothelial and smooth muscle cells. Brain Res. 381:1986;363-367.
251. Steulet A.-F., Stöcklin K., Wicki P., Waldmeier P. Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis. Neurochem. Res. 18:1993;1131-1136.
252. Stocchi F., Nordera G., Marsden C.D. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin. Neuropharmacol. 20:1997;95-115.
253. Sundberg S., Scheinin M., Ojala-Karlsson P., Kaakkola S., Akkila J., Gordin A. Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone. Clin. Pharmacol. Ther. 48:1990;356-364.
254. Sundberg S., Scheinin M., Illi A., Akkila J., Gordin A., Keränen T. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br. J. Clin. Pharmacol. 36:1993;451-456. a.
255. Sundberg S., Scheinin M., Ojala-Karlsson P., Akkila J., Gordin A. The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition. Eur. J. Clin. Pharmacol. 44:1993;287-290. b.
256. Suzuki Y.J., Tsuchiya M., Safadi A., Kagan V.E., Packer L. Antioxidant properties of nitecapone (OR-462). Free Radic. Biol. Med. 13:1992;517-525.
257. Sweet R.D., McDowell F.H. Plasma DOPA concentrations and the "on-off" effect after chronic treatment of Parkinson's disease. Neurology. 24:1974;953-956.
258. Syvanen A.C., Tilgmann C., Rinne J., Ulmanen I. Genetic polymorphism of catechol-O-methyltransferase (COMT). correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland Pharmacogenetics. 7:1997;65-71.
259. Taskinen J., Wikberg T., Ottoila P., Kanner L., Lotta T., Pippuri A., Bäckström R. Identification of major metabolites of the catechol-O-methyltransferase inhibitor nitecapone in human urine. Drug Metab. Dispos. 19:1991;178-183.
260. ångström B. Central action of benserazide after COMT inhibition demostrated in vivo by PET. J. Neural Transm. (Gen. Sect.). 85:1991;11-17.
261. Tenhunen J. Characterization of the rat catechol-O-methyltransferase gene proximal promoter. identification of a nuclear protein-DNA interaction that contributes to the tissue-specific regulation DNA Cell Biol. 15:1996;461-473.
262. Tenhunen J., Salminen M., Jalanko A., Ukkonen S., Ulmanen I. Structure of the rat catechol-O-methyltransferase gene. separate promoters are used to produce mRNAs for soluble and membrane-bound forms of the enzyme DNA Cell Biol. 12:1993;253-263.
263. Tenhunen J., Salminen M., Lundström K., Kiviluoto T., Savolainen R., Ulmanen I. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur. J. Biochem. 223:1994;1049-1059.
264. Tilgmann C., Kalkkinen N. Purification and partial characterization of rat liver soluble catechol-O-methyltransferase. FEBS Lett. 264:1990;95-99.
265. Tilgmann C., Kalkkinen N. Purification and partial sequence analysis of the soluble catechol-O-methyltransferase from human placenta. comparison to the rat liver enzyme Biochem. Biophys. Res. Commun. 174:1991;995-1002.
266. Tilgmann C., Ulmanen I. Purification methods of mammalian catechol-O-methyltransferases. J. Chromatogr. B. Biomed. Appl. 684:1996;147-161.
267. Tilgmann C., Melen K., Lundström K., Jalanko A., Julkunen I., Kalkkinen N.M., Ulmanen I. Expression of recombinant soluble and membrane-bound catechol-O-methyltransferase in eucaryotic cells and identification of the respective enzymes in rat brain. Eur. J. Biochem. 207:1992;813-821.
268. Timm U., Erdin R. Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection. J. Chromatogr. 593:1992;63-68.
269. Tissot R., Bartholini G., Pletscher A. Drug-induced changes of extracerebral dopa metabolism in man. Arch. Neurol. 20:1969;187-190.
270. Tohgi H., Abe T., Kikuchi T., Takahashi S., Nozaki Y. The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease. Neurosci. Lett. 132:1991;19-22.
271. Tohgi H., Abe T., Yamazaki K., Saheki M., Takahashi S., Tsukamoto Y. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease. correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement Neurosci. Lett. 192:1995;165-168.
272. Tolosa E.S., Martin W.E., Cohen H.P., Jacobson R.L. Patterns of clinical response and plasma DOPA levels in Parkinson's disease. Neurology. 25:1975;177-183.
273. Törnwall M., Männistö P.T. Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission. Pharmacol. Toxicol. 69:1991;64-70.
274. Törnwall M., Männistö P.T. Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats. Eur. J. Pharmacol. 250:1993;77-84.
275. Törnwall M., Tuomainen P., Männistö P.T. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase. Eur. J. Pharmacol. 239:1993;39-45.
276. Törnwall M., Kaakkola S., Tuomainen P., Kask A., Männistö P.T. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism. a microdialysis study in rats Br. J. Pharmacol. 112:1994;13-18.
277. Tunnicliff G., Ngo T.T. Kinetics of rat brain soluble catechol-O-methyltransferase and its inhibition by substrate analogues. Int. J. Biochem. 15:1983;733-738.
278. Tuomainen P., Reenilä I., Männistö P.T. Validation of assay of catechol-O-methyltransferase activity in human erythrocytes. J. Pharm. Biomed. Anal. 14:1996;515-523. a.
279. Tuomainen P., Törnwall M., Männistö P.T. Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargiline. a microdialysis study in anaesthetized rats Pharmacol. Toxicol. 78:1996;392-396. b.
280. Uitti R.J., Calne D.B. Pathogenesis of idiopathic parkinsonism. Eur. Neurol. 33(Suppl. 1):1993;6-23.
281. Ulmanen I., Lundström K. Cell-free synthesis of rat and human catechol-O-methyltransferase. Eur. J. Biochem. 202:1991;1013-1020.
282. Verhagen-Kamerbeek W.D.J., Hazemeijer I., Korf J., Lakke J.P.W.F. Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS. J. Neural Transm. (P-D Sect.). 6:1993;17-26.
283. Verhagen Metman L., Locatelli E.R., Bravi D., Mouradian M.M., Chase T.N. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology. 48:1997;369-372.
284. Vidgren J., Svensson L.A., Liljas A. Crystal structure of catechol O-methyltransferase. Nature. 368:1994;354-358.
285. Vieira-Coelho M.A., Soares-da-Silva P. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br. J. Pharmacol. 117:1996;516-520.
286. Vieregge P. Genetic factors in the etiology of idiopathic Parkinson's disease. J. Neural Transm. (P.-D. Sect.). 8:1994;1-37.
287. Wada G.H., Fellman J.H. 2,4,5-Trihydroxyphenylacetic acid. a metabolite of L-3,4-dihydroxyphenylalanine Biochemistry. 12:1973;5212-5217.
288. Wade D.N., Mearrick P.T., Morris J.L. Active transport of L-DOPA in the intestine. Nature. 242:1973;463-465.
289. Wade D.N., Mearrick P.T., Birkett D.J., Morris J. Variability of L-DOPA absorption in man. Aust. N.Z. J. Med. 4:1974;138-143.
290. Wade L.A., Katzman R. Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier. J. Neurochem. 25:1975;837-842. a.
291. Wade L.A., Katzman R. 3-O-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci. 17:1975;131-136. b.
292. Waldmeier P.C., Baumann P.A., Feldtrauer J.-J., Hauser K., Bittiger H., Bischoff S., von Sprecher G. CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch. Pharmacol. 342:1990;305-311. a.
293. Waldmeier P.C., De Herdt P., Maitre L. Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-DOPA in the rat. J. Neural Transm. Suppl. 32:1990;381-386. b.
294. Waters C.H., Kurth M., Bailey P., Shulman L.M., LeWitt P., Dorflinger E., Deptula D., Pedder S., the Tolcapone Stable Study Group Tolcapone in stable Parkinson's disease. efficacy and safety of long-term treatment Neurology. 49:1997;665-671.
295. Weinshilboum R.M. Human erythrocyte catechol-O-methyltransferase. correlation with lung and kidney activity Life Sci. 22:1978;625-630.
296. Weinshilboum R.M. Human pharmacogenetics of methyl conjugation. Fed. Proc. 43:1984;2303-2307.
297. Weinshilboum R.M., Raymond F.A. Inheritance of low erythrocyte catechol-O-methyltransferase activity in man. Am. J. Hum. Genet. 29:1977;125-135.
298. Weinshilboum R.M., Raymond F.A., Elveback L.R., Weidman W.H. Correlation of erythrocyte catechol-O-methyltransferase activity between siblings. Nature. 252:1974;490-491.
299. Weiss J.L., Cohn C.K., Chase T.N. Reduction of catechol-O-methyltransferase activity by chronic L-dopa therapy. Nature. 234:1971;218-219.
300. 14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile. Eur. J. Drug Metab. Pharmacokinet. 19:1994;125-135.
301. Wikberg T., Ottoila P., Taskinen J. Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog. Eur. J. Drug Metab. Pharmacokinet. 18:1993;359-367. a.
302. Wikberg T., Vuorela A., Ottoila P., Taskinen J. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab. Dispos. 21:1993;81-92. b.
303. Wilhelmsen K.C., Wszolek Z.K. Is there a genetic susceptibility to idiopathic parkinsonism? Parkinsonism Relat. Disord. 1:1995;73-84.
304. Winqvist R., Lundström K., Salminen M., Laatikainen M., Ulmanen I. The human catechol-O-methyltransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BglI. Cytogenet. Cell Genet. 59:1992;253-257.
305. Winter H., Herschel M., Propping P., Friedl W., Vogel F. A twin study of three enzymes (DBH, COMT, MAO) of catecholamine metabolism. Psychopharmacology. 57:1978;63-69.
306. Wood N. Genes and parkinsonism. J. Neurol. Neurosurg. Psychiatry. 62:1997;305-309.
307. Woodard R.W., Tsai M.D., Floss H.G., Crooks P.A., Coward J.K. Stereochemical course of the transmethylation catalyzed by catechol O-methyltransferase. J. Biol. Chem. 255:1980;9124-9127.
308. Xie T., Ho S.L., Li L.S.W., Ma O.C.K. G/A1947 Polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov. Disord. 12:1997;426-427.
309. Yamamoto M., Yokochi M., Kuno S., Hattori Y., Tsukamoto Y., Narabayashi H., Tohgi H., Mizuno Y., Kowa H., Yanagisawa N., Kanazawa I. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. J. Neural Transm. 104:1997;229-236.
310. Yassin M.S., Cheng H., Ekblom J., Oreland L. Inhibitors of catecholamine metabolising enzymes cause changes in S-adenosylmethionine and S-adenosylhomocysteine in the rat brain. Neurochem. Int. 32:1998;53-59.
311. Zürcher G., Colzi A., Da Prada M. Ro 40-7592. inhibition of COMT in rat brain and extracerebral tissues J. Neural Transm. Suppl. 32:1990;375-380. a.
312. Zürcher G., Keller H.H., Kettler R., Borgulya J., Bonetti E.P., Eigenmann R., Da Prada M. Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase. a pharmacological study in rats Adv. Neurol. 53:1990;497-503. b.
313. Zürcher G., Dingemanse J., Da Prada M. Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings. Adv. Neurol. 60:1993;641-647.
314. Zürcher G., Da Prada M., Dingemanse J. Assessment of catechol-O-methyltransferase activity and its inhibition in erythrocytes of animals and humans. Biomed. Chromatogr. 10:1996;32-36.